Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Bioorg Med Chem Lett ; 77: 129005, 2022 12 01.
Article in English | MEDLINE | ID: mdl-36174834

ABSTRACT

Here is reported the design and synthesis of a series of highly potent and selective α2C antagonists using benzodioxine methyl piperazine as a central scaffold by pharmacophoric analysis to improve the pharmacokinetics of suboptimal clinical candidate molecules.


Subject(s)
Receptors, Adrenergic, alpha-2
2.
Bioorg Med Chem Lett ; 69: 128783, 2022 08 01.
Article in English | MEDLINE | ID: mdl-35569686

ABSTRACT

In this manuscript, we report a series of benzodioxine methyl piperidine derivatives as highly potent and selective α2C antagonists by ligand design to improve the pharmacokinetics of a previous candidate molecule.


Subject(s)
Dioxins , Receptors, Adrenergic, alpha-2 , Piperidines/pharmacology
3.
Addict Biol ; 24(6): 1191-1203, 2019 11.
Article in English | MEDLINE | ID: mdl-30421860

ABSTRACT

Drugs of abuse induce widespread synaptic adaptations in the mesolimbic dopamine (DA) neurons. Such drug-induced neuroadaptations may constitute an initial cellular mechanism eventually leading to compulsive drug-seeking behavior. To evaluate the impact of GABAB receptors on addiction-related persistent neuroplasticity, we tested the ability of orthosteric agonist baclofen and two positive allosteric modulators (PAMs) of GABAB receptors to suppress neuroadaptations in the ventral tegmental area (VTA) and reward-related behaviors induced by ethanol and cocaine. A novel compound (S)-1-(5-fluoro-2,3-dihydro-1H-inden-2-yl)-4-methyl-6,7,8,9-tetrahydro-[1,2,4]triazolo[4,3-a]quinazolin-5(4H)-one (ORM-27669) was found to be a GABAB PAM of low efficacy as agonist, whereas the reference compound (R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one (rac-BHFF) had a different allosteric profile being a more potent PAM in the calcium-based assay and an agonist, coupled with potent PAM activity, in the [35 S] GTPγS binding assay in rat and human recombinant receptors. Using autoradiography, the high-efficacy rac-BHFF and the low-efficacy ORM-27669 potentiated the effects of baclofen on [35 S] GTPγS binding with identical brain regional distribution. Treatment of mice with baclofen, rac-BHFF, or ORM-27669 failed to induce glutamate receptor neuroplasticity in the VTA DA neurons. Pretreatment with rac-BHFF at non-sedative doses effectively reversed both ethanol- and cocaine-induced plasticity and attenuated cocaine i.v. self-administration and ethanol drinking. Pretreatment with ORM-27669 only reversed ethanol-induced neuroplasticity and attenuated ethanol drinking but had no effects on cocaine-induced neuroplasticity or self-administration. These findings encourage further investigation of GABAB receptor PAMs with different efficacies in addiction models to develop novel treatment strategies for drug addiction.


Subject(s)
Central Nervous System Depressants/pharmacology , Cocaine/pharmacology , Dopamine Uptake Inhibitors/pharmacology , Dopaminergic Neurons/drug effects , Ethanol/pharmacology , GABA Modulators/pharmacology , Neuronal Plasticity/drug effects , Receptors, GABA-B/drug effects , Allosteric Regulation , Animals , Baclofen/pharmacology , Behavior, Animal/drug effects , Benzofurans/pharmacology , CHO Cells , Cricetulus , GABA-B Receptor Agonists/pharmacology , Humans , Mice , Quinazolinones/pharmacology , Rats , Receptors, Glutamate/drug effects , Receptors, Glutamate/metabolism , Reward , Self Administration , Ventral Tegmental Area/cytology , Ventral Tegmental Area/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...